- AgraFlora Organics (AGRA) has begun research and development trials at its edibles manufacturing facility in Winnipeg, Manitoba
- The company recently received an essential CRA tax license, and can now create test cannabis edible products
- AgraFlora has already used its R&D license to formulate cannabis-activated pectin and gelatin gummies, hard candy, and sugar-free variants
- The company applied for a Health Canada processing license in May, and expects to receive it in 2020’s fourth quarter
- AgraFlora Organics (AGRA) is up 12.50 per cent and is currently trading at 4.5 cents per share
AgraFlora Organics (AGRA) has begun research and development trials at its edibles manufacturing facility in Winnipeg, Manitoba.
The company recently received an essential CRA tax license, and can now create test cannabis edible products. This is occurring in AgraFlora’s Health Canada-licensed research and development lab within its 51,000 square foot edibles manufacturing facility.
AgraFlora has already used its R&D license to formulate a number of Cannabis 2.0 products. These include cannabis-activated pectin and gelatin gummies, hard candy, and sugar-free variants.
James Fletcher, the founder and operational manager of AgraFlora’s subsidiary, The Edibles and Infusions Corporation (EIC), commented on the company’s R&D efforts.
“As part of the R&D program, we have begun a testing project with Agilent to improve testing standards, methods, and ensure consistent quality.
“Our efficient and highly automated R&D production allows us to provide a variety of sample products for our prospective clients to try for their established brands,” he said.
In late May, EIC applied for a processing license from Health Canada, for the manufacturing facility in Manitoba. The application included submitting a comprehensive Site Evidence Package for the fully automated, production-ready facility.
Despite already having a Research and Development license from Health Canada, the company can not progress further without the Processing License. AgraFlora and EIC hope to receive the license from Health Canada by the fourth quarter of 2020.
If this is achieved, the company’s timeline indicates that it could reach its first packaged sales from the facility within the same quarter.
AgraFlora Organics (AGRA) is up 12.50 per cent and is trading at 4.5 cents per share at 1:06pm EDT.